Cassava Sciences (NSDQ:SAVA) announced that its experimental Alzheimer’s drug simufilam was associated with an improved cognition score at 12 months. Specifically, recipients of the drug showed a 3.2 point improvement on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) from baseline to month 12.
Austin, Texas–based Cassava also announced that 68% of study participants demonstrated improved ADAS-Cog scores at 12 months. Among participants with improvement, the average increase in ADAS-Cog score was 6.8 points.
The data came from a pre-planned interim analysis of an open-label study.
“We look forward to the initiation of a randomized, double-blind, placebo-controlled pivotal Phase 3 clinical program with simufilam in people with Alzheimer’s disease,” said Remi Barbier, the company’s CEO, in a statement.
Investors were apparently unimpressed, sending SAVA shares down 1.04% apiece to $52.31. Sh…